ADARx reports Q3 2026 results, Fast Track for onvuzosiran, three agazisiran trials ongoingNov 12Quarterly updateADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals closes IPO and AbbVie private placementSep 28FinancingAbbVieADARx Pharmaceuticals, Inc.
ADARx prices IPO at $17 per share, AbbVie to buy stakeSep 25FinancingAbbVieADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals files S-1 for Nasdaq IPO under ticker ADRXSep 4FinancingADARx Pharmaceuticals, Inc.inclisiran sodium